Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

VDA-1102 studied in new phase II trial for early forms of cutaneous T-cell lymphoma

Feb. 10, 2021

Basilea reports cohort 1 data from phase II study of derazantinib in intrahepatic cholangiocarcinoma

Feb. 10, 2021

Phase III study of napabucasin in metastatic colorectal cancer misses primary endpoints

Feb. 10, 2021

U.S. researchers divulge new immunotherapeutic constructs for cancer

Feb. 10, 2021

Shouyao Holdings (Beijing) identifies new Ret inhibitors

Feb. 10, 2021

Teon Therapeutics patents new adenosine A2A receptor antagonists

Feb. 10, 2021

NSC-765690 and NSC-765599 show antitumor activity against NCI60 human tumor cell lines

Feb. 10, 2021

SorLA identified as a target in anti-HER2-resistant HER2-positive breast cancer

Feb. 10, 2021

European Commission approves Inrebic for newly diagnosed and previously treated myelofibrosis

Feb. 9, 2021

FDA clears Catapult's IND for phase I trial of CAP-100 in CLL

Feb. 9, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...